Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study

MLA

Nabil Baba-Hamed, et al. “Withholding Anti-EGFR: Impact on Outcome of RAS Wild-Type Metastatic Colorectal Tumours (WAIT OR ACT): A Multicentric AGEO Study.” Annals of Oncology, vol. 29, Oct. 2018, p. viii163. EBSCOhost, https://doi.org/10.1093/annonc/mdy281.033.

APA

Nabil Baba-Hamed, Dewi Vernerey, Simon Pernot, L. Mineur, Romain Coriat, D. Smith, J.-M. Gornet, M.P. Galais, S. Racine Doat, L-J. Palmieri, David Tougeron, O. Bouche, J.-P. Metges, M. Hassine, Carole Vitellius, A.L. Bignon Bretagne, Astrid Lièvre, Stéphane Obled, Benoit Rousseau, & Victoire Granger. (2018). Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study. Annals of Oncology, 29, viii163. https://doi.org/10.1093/annonc/mdy281.033

Chicago

Nabil Baba-Hamed, Dewi Vernerey, Simon Pernot, L. Mineur, Romain Coriat, D. Smith, J.-M. Gornet, et al. 2018. “Withholding Anti-EGFR: Impact on Outcome of RAS Wild-Type Metastatic Colorectal Tumours (WAIT OR ACT): A Multicentric AGEO Study.” Annals of Oncology 29 (October): viii163. doi:10.1093/annonc/mdy281.033.